PB-119 is a long-acting GLP-1 receptor agonist developed by PegBio. The phase II clinical trials of PB-119 for type 2 diabetes mellitus have been completed in China and US. The trial results demonstrated that PB-119 has remarkable effects on reducing HbA1c levels with potential benefit in weight loss and overall improvement in lipid metabolic profiling. In addition, patients receiving PB-119 treatment show good safety profile. Results from the China phase II clinical study were published in the Diabetologia in 2020.

PB-119 is currently undergoing multiple phase III clinical trials in China, including PB-119 alone and in combination with metformin, basal insulin, or SGLT-2 inhibitor, respectively, for the treatment of type 2 diabetes mellitus. The cardiovascular outcome trial in patients with type 2 diabetes has also been approved by the CDE.

PB-119 is intended for single-dose administration without dose titration. Along with the use of an automated disposable pen injector, PB-119 possesses the advantage of the convenience of usage that will significantly improve the quality of life of million diabetic patients.